Newsletter April 2019

GNA Biosolutions partners with Boehringer Ingelheim

Development of an ASF diagnostic test with GNA's portable molecular diagnostic platform PHAROS 400

Development of an ASF diagnostic test with GNA’s portable molecular diagnostic platform PHAROS 400

GNA Biosolutions and Boehringer Ingelheim have entered into a research partnership. The aim of the collaboration between the Martinsried-based SHS portfolio company and one of the world’s leading animal health companies is to develop a rapid diagnostic test for African Swine Fever (ASF). The portable molecular diagnostic platform produced by GNA Biosolutions will be used to control the worldwide spread of this deadly disease. “We are delighted to be working with Boehringer Ingelheim. It further highlights the role GNA Biosolutions is playing in the rapidly evolving field of laboratory diagnostics and extends the application of our Pulse Controlled Amplification (PCA) technology to animal welfare,” said Dr. Ullerich, co-founder and CEO of GNA Biosolutions.
In 2015, SHS’ fourth fund invested in GNA Biosolutions together with existing and new investors.


Key Facts
Year established: 2010
Business purpose: Development of molecular diagnostic tests (POC/PON) based on at least 10x faster laser PCR technology to accelerate time-critical diagnoses (e.g. infections) for the benefit of the patient.
Products: PharosV8
Location: Martinsried


>> next article
<< previous article
<< back to index